title: Effect of aspirin in prevention of adverse pregnancy outcome in women with elevated alpha-fetoprotein.
abstract: BACKGROUND
  To evaluate the effect of low-dose aspirin in prevention of adverse pregnancy outcomes (APO) in women with second trimester alpha-fetoprotein (AFP) >2.5 multiple of median (MOM) and to compare aspirin effect on women with normal and abnormal uterine artery (UtA) Doppler. The primary outcome was the adverse pregnancy outcome.
  
  
  METHODS
  This randomized controlled trial was conducted in singleton pregnant women, who had unexplained AFP >2.5 MOM and gestational age between 15 and 18 weeks of gestation. They were assigned randomly to receive either aspirin (N = 65) or control (N = 68). UtA Doppler velocimetry studies were performed at the time of targeted ultrasonographic exam.
  
  
  RESULTS
  Two groups were comparable regarding the maternal characteristics. The frequency of APO in aspirin and control groups were 26.1% versus 44.1% (p = 0.045), the frequency of preterm delivery before 34 weeks were 3.2% versus 22.0% in aspirin and control group, p = 0.001. Other outcomes were similar in both groups. The frequency of adverse outcomes in women with abnormal UtA Doppler was 39.1% in aspirin and 60.0% in control group, p = 0.556.
  
  
  CONCLUSIONS
  Low-dose aspirin reduces APO and delivery before 34 weeks of gestation in pregnant women with unexplained elevated AFP.
authors.affiliation: Perinatology Division, OB/GYN Department, Tehran University of Medical Sciences , Tehran , Islamic Republic of Iran.
authors.forename: Soghra
authors.initials: S
authors.lastname: Khazardoost
authors.forename: Sanaz
authors.initials: S
authors.lastname: Mousavi
authors.forename: Sedigheh
authors.initials: S
authors.lastname: Borna
authors.forename: Sedigheh
authors.initials: S
authors.lastname: Hantoushzadeh
authors.forename: Azin
authors.initials: A
authors.lastname: Alavi
authors.forename: Naser
authors.initials: N
authors.lastname: Khezerlou
mesh_terms: D000328:Adult; D001241:Aspirin / Q000627:therapeutic use*; D005260:Female; D005313:Fetal Death / Q000517:prevention & control; D006801:Humans; D011225:Pre-Eclampsia / Q000503:physiopathology / Q000517:prevention & control; D011247:Pregnancy; D011248:Pregnancy Complications / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control*; D011256:Pregnancy Outcome / Q000453:epidemiology; D011262:Pregnancy Trimester, Second; D047928:Premature Birth / Q000453:epidemiology / Q000517:prevention & control; D011673:Pulsatile Flow / Q000187:drug effects; D055988:Uterine Artery / Q000187:drug effects / Q000502:physiology; D055815:Young Adult; D000509:alpha-Fetoproteins / Q000378:metabolism*
chemical_list: D000509:alpha-Fetoproteins; D001241:Aspirin